You are here
Propecia (finasteride 5mg) manufactured by pharmaceutical Giant Merck & Co. was approved by FDA in 1992 for the treatment of bothersome symptoms in men with benign prostatic hyperplasia (also referred to as BPH or an enlarged prostate), Propecia (finasteride 1 mg) was approved by FDA in 1997 for use in males only and is indicated for the treatment of male pattern hair loss.
Many men turned to Propecia believing drug makers claims, and gradually their lives changed to worst, as the full proof information about the side effects of the drugs were not shared by the manufacturers.
Major complications caused by Propecia
- High-grade prostate cancer
- Erectile dysfunction
- Ejaculation disorder
- Reduced sexual sensation
- Diminished or reduced libido
- Genital shrinkage
- Cognitive impairment
It is observed that even after Propecia is discontinued, the complications do not recover.
In June 2011, it was evidenced that Propecia increases the risk of prostate cancer, FDA announced new labeling requirements.
There was another change announced for Propecia in April 2012, which suggested that label should include warnings about libido disorders, ejaculation disorders, and orgasm disorders that continued after discontinuation of the drug.
Many sexual dysfunction cases against Propecia were pending which were centralized to Eastern district court of New York on April 16, 2012. These cases were consolidated into MDL 2331, a multidistrict litigation led by U.S. District Judge John Gleeson which grew to more than 700 lawsuits, with the first trails set to begin in October 2016. A huge number of cases are pending in New Jersey state courts.
Evidence to be looked for in potential cases
- Usage of Propecia in Pharmacy Records
- Indication of Propecia usage in Medical Records
- Complication and treatment after Propecia usage/Persistent sexual dysfunction
Medical Record Review and claim validation of Propecia case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.